ICU Medical, Inc. (NASDAQ:ICUI) CEO Sells $1,961,520.00 in Stock

ICU Medical, Inc. (NASDAQ:ICUI) CEO Vivek Jain sold 12,000 shares of ICU Medical stock in a transaction that occurred on Tuesday, September 3rd. The stock was sold at an average price of $163.46, for a total value of $1,961,520.00. Following the completion of the transaction, the chief executive officer now directly owns 104,593 shares in the company, valued at $17,096,771.78. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Vivek Jain also recently made the following trade(s):

• On Friday, August 16th, Vivek Jain sold 12,000 shares of ICU Medical stock. The stock was sold at an average price of $156.04, for a total transaction of $1,872,480.00.

ICU Medical Trading Down 0.5 %

Shares of ICUI stock opened at $162.22 on Thursday. The firm has a fifty day moving average of $137.38 and a 200-day moving average of $115.92. The stock has a market cap of $3.95 billion, a price-to-earnings ratio of -66.21 and a beta of 0.69. ICU Medical, Inc. has a 52-week low of $78.28 and a 52-week high of $166.46. The company has a debt-to-equity ratio of 0.76, a quick ratio of 1.08 and a current ratio of 2.41.

ICU Medical (NASDAQ:ICUI) last posted its quarterly earnings results on Wednesday, August 7th. The medical instruments supplier reported $1.56 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.00 by $0.56. The firm had revenue of $596.50 million during the quarter, compared to analyst estimates of $556.64 million. ICU Medical had a negative net margin of 3.07% and a positive return on equity of 5.01%. The company’s quarterly revenue was up 8.6% compared to the same quarter last year. During the same quarter in the prior year, the business posted $1.58 earnings per share. On average, equities research analysts forecast that ICU Medical, Inc. will post 3.76 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

ICUI has been the subject of a number of research reports. Raymond James increased their price target on shares of ICU Medical from $135.00 to $158.00 and gave the company an “outperform” rating in a report on Thursday, August 8th. Needham & Company LLC reiterated a “hold” rating on shares of ICU Medical in a research note on Thursday, August 8th. Finally, KeyCorp boosted their price target on ICU Medical from $136.00 to $147.00 and gave the company an “overweight” rating in a research note on Thursday, August 8th. Two equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $138.33.

Hedge Funds Weigh In On ICU Medical

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Charles Schwab Investment Management Inc. raised its stake in ICU Medical by 14.1% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 192,773 shares of the medical instruments supplier’s stock worth $19,227,000 after acquiring an additional 23,816 shares in the last quarter. Principal Financial Group Inc. boosted its position in ICU Medical by 37.8% in the fourth quarter. Principal Financial Group Inc. now owns 107,335 shares of the medical instruments supplier’s stock valued at $10,706,000 after buying an additional 29,464 shares in the last quarter. Scout Investments Inc. grew its stake in ICU Medical by 16.3% during the first quarter. Scout Investments Inc. now owns 51,819 shares of the medical instruments supplier’s stock worth $5,463,000 after buying an additional 7,272 shares during the last quarter. Maryland State Retirement & Pension System acquired a new stake in shares of ICU Medical during the fourth quarter worth approximately $890,000. Finally, Wakefield Asset Management LLLP bought a new position in shares of ICU Medical in the first quarter valued at approximately $989,000. Institutional investors own 96.10% of the company’s stock.

About ICU Medical

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.